According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...

PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

You can still live a full life with geographic atrophy (GA). Even though your vision may be different, GA doesn’t lead to total blindness. You can use your remaining vision and make certain ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

In an interview with Ophthalmology Times, Quan Dong Nugyen, MD, MSc, discusses ongoing research into Tinlarebant, an ...

CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...